Biotech China Expansion Healthcare Wuhan
Visara has acquired the global exclusive rights, excluding Greater China, in the ophthalmology field from Wuhan Haite Biopharma for HT006.2.2 to develop and commercialize. The company plans to develop HT006.2.2 under the codename VIS-102 as its second clinical-stage project, expanding its ophthalmology pipeline from retinal vascular diseases to ocular surface diseases. HT006.2.2 aims to provide a more convenient treatment option for patients with neurotrophic keratitis. This strategic move by Visara marks a significant expansion in its ophthalmology offerings by securing the rights to develop and market HT006.2.2 globally, setting the stage for potential advancements in treating neurotrophic keratitis. The decision…
News Timeline:
Track the development of this news story across the Internet.